The lead compound is MRG-001, which has been extensively tested in preclinical models for several indications and has successfully entered phase II clinical trials.
MedRegen is committed to advancing its pipeline by launching multiple clinical trials in 2025-2026 aimed at exploring additional indications and expanding the therapeutic potential of MRG-001. These trials will address unmet medical needs, further validate the drug’s safety and efficacy, and support regulatory filings for broader use.
MRG-002 is under preclinical development for the indication of wound healing and certain liver diseases.
